Literature DB >> 15080567

Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.

Françoise Imbert-Bismut1, Djamila Messous, Vincent Thibault, Vincent Thibaut, Rob B Myers, Annie Piton, Dominique Thabut, Laure Devers, Bernard Hainque, Anne Mercadier, Thierry Poynard.   

Abstract

Combinations of tests comprising alpha2-macroglobulin, haptoglobin, apolipoprotein Al, gamma-glutamyltransferase, total bilirubin (Fibrotest) and alanine aminotransferase (Actitest) are being developed as alternatives to liver biopsy in patients with chronic hepatitis C. The aim of this study was to assess in the same laboratory the impact of parameter assay variations on Fibrotest and Actitest results and intra-patient reproducibility of the two tests. The stability of the samples for each test was studied after storage at -80 degrees C and -20 degrees C. Within-run, between-run and total imprecision for each parameter assay, and for Fibrotest and Actitest results, were determined. Transferability of assay results between different analyzers was studied. Intra-patient reproducibility was assessed in 55 hospitalized patients. Fibrotest and Actitest reference ranges were determined in 300 blood donors (reference group). The stability of the parameters was affected by serum storage at -20 degrees C only. The impact of parameter analytical variability on Fibrotest and Actitest results was less than 10% and intra-patient reproducibility was acceptable (p > 0.05). The transferability between different analyzers of results of assays performed under the same standardized and calibration conditions was excellent. Fibrotest and Actitest reference ranges in blood donors were (mean+/-SE) 0.075+/-0.004 and 0.068+/-0.004, respectively. The low intra-laboratory and intra-patient variability in Fibrotest and Actitest results confirm Fibrotest and Actitest reliability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15080567     DOI: 10.1515/CCLM.2004.058

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  32 in total

Review 1.  Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C.

Authors:  Laurent Castera; Jean-Michel Pawlotsky
Journal:  MedGenMed       Date:  2005-11-09

Review 2.  Liver elastography, comments on EFSUMB elastography guidelines 2013.

Authors:  Xin-Wu Cui; Mireen Friedrich-Rust; Chiara De Molo; Andre Ignee; Dagmar Schreiber-Dietrich; Christoph F Dietrich
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

3.  Applicability and variability of liver stiffness measurements according to probe position.

Authors:  Patrick Ingiliz; Kim Pav Chhay; Mona Munteanu; Pascal Lebray; Yen Ngo; Dominique Roulot; Yves Benhamou; Dominique Thabut; Vlad Ratziu; Thierry Poynard
Journal:  World J Gastroenterol       Date:  2009-07-21       Impact factor: 5.742

4.  Non-invasive assessment of liver fibrosis in chronic hepatitis C.

Authors:  Laurent Castera
Journal:  Hepatol Int       Date:  2011-01-20       Impact factor: 6.047

5.  Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease.

Authors:  Jonathan Barr; Mercedes Vázquez-Chantada; Cristina Alonso; Miriam Pérez-Cormenzana; Rebeca Mayo; Asier Galán; Juan Caballería; Antonio Martín-Duce; Albert Tran; Conrad Wagner; Zigmund Luka; Shelly C Lu; Azucena Castro; Yannick Le Marchand-Brustel; M Luz Martínez-Chantar; Nicolas Veyrie; Karine Clément; Joan Tordjman; Philippe Gual; José M Mato
Journal:  J Proteome Res       Date:  2010-09-03       Impact factor: 4.466

6.  Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

Authors:  Shira Zelber-Sagi; Muriel Webb; Nimer Assy; Laurie Blendis; Hanny Yeshua; Moshe Leshno; Vlad Ratziu; Zamir Halpern; Ran Oren; Erwin Santo
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 7.  Is liver biopsy still needed in children with chronic viral hepatitis?

Authors:  Maria Pokorska-Śpiewak; Barbara Kowalik-Mikołajewska; Małgorzata Aniszewska; Magdalena Pluta; Magdalena Marczyńska
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

8.  Serum hyaluronic acid: a promising marker of hepatic fibrosis in chronic hepatitis B.

Authors:  Gamal Shiha
Journal:  Saudi J Gastroenterol       Date:  2008-10       Impact factor: 2.485

9.  Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.

Authors:  Mireen Friedrich-Rust; William Rosenberg; Julie Parkes; Eva Herrmann; Stefan Zeuzem; Christoph Sarrazin
Journal:  BMC Gastroenterol       Date:  2010-09-09       Impact factor: 3.067

Review 10.  Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage.

Authors:  Pamela Valva; Daniela A Ríos; Elena De Matteo; Maria V Preciado
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.